View Author
patient treatment cancer chemotherapy cohort study breast coxib cohort entry date study cohort therapy reference cohort rofecoxib 2007 john wiley nsnsaid breast cancer patients entry reference withdrawal cardiotoxic breast cancer event hospital adjuvant tumour status incidence rates period non-cardiotoxic chemotherapy nsaid hormone receptor status cardiotoxic chemotherapy incidence change month women drug safety rofecoxib withdrawal diagnosis follow-up stage breast cancer netherland non-cardiotoxic stage lymph node status atc code disease characteristic receptor prescription number analgesic table wiley factor safety acetaminophen guideline pharmacoepidemiology group 10.1002/ baseline treatment changes radiation therapy opioid cancer centre copyright pattern histologic tumour grade 100.0 lymph probability hormone pharmo 2 years classi nsaid treatment radiation cardiotoxicity hospital admissions
3 Most Recent Publications
|
Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands
(Article)
Sukel, M.P.P. Poll-Franse, L.V. van de Nieuwenhuijzen, G.A.P. Vreugdenhil, G. Herings, R.M.C. Coebergh, J.W.W. Voogd, A.C. |
2008-09-01
|
|
Incidence of cardiovascular events in breast cancer patients receiving chemotherapy in clinical practice
(Article)
Sukel, M.P.P. Breekveldt-Postma, N.S. Erkens, J.A. Linden, P.D. van der Beiderbeck, A.B. Coebergh, J.W.W. Herings, R.M.C. |
2008-02-01
|
|
Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal
(Article)
Sukel, M.P.P. Linden, M.W. van der Chen, C. Erkens, J.A. Herings, R.M.C. |
2008-01-01
|
